Last reviewed · How we verify
NCT04041713
A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome
Phase 2 trial testing Rett-T in Rett Syndrome in 35 participants. Not yet recruiting.
30 November 2026
Quick facts
| Lead sponsor | Holland Bloorview Kids Rehabilitation Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 1 October 2025 |
| Primary completion | 30 November 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Rett-T — full drug profile →
- Placebo
Conditions studied
- Rett Syndrome — all drugs for Rett Syndrome →
Sponsor
Holland Bloorview Kids Rehabilitation Hospital
Who can join
Adults 2 to 21, female only, with Rett Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will examine the potential efficacy and safety of Rett-T for core motor deficits of Rett syndrome, and will explore biological markers of safety and treatment response.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Rett Syndrome: The Emerging Landscape of Treatment Strategies.
Percy AK, Ananth A, Neul JL. · · 2024 · cited 20× · PMID 39251501 · DOI 10.1007/s40263-024-01106-y
Verify or expand the search:
- PubMed search for NCT04041713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rett Syndrome
Currently open trials in the same condition.
- NCT06840496 — To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome · Phase 3 · recruiting
- NCT07151950 — Obi Medical Robot: Evaluating Effectiveness Related to Usability · active not recruiting
- NCT06856759 — Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome · EARLY_PHASE1 · recruiting
- NCT07418905 — Technology-supported Motor Rehabilitation for People With Rett Syndrome · NA · active not recruiting
- NCT06152237 — Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) · Phase 1, PHASE2 · active not recruiting
Other Holland Bloorview Kids Rehabilitation Hospital trials
Trials by the same sponsor.
- NCT07360171 — Validity Assessment of Sensors for Movement Tracking With Children/Youth With Diverse Neuromotor Abilities · not yet recruiting
- NCT06341127 — Fluoxetine in KCNC1-related Disorder · NA · completed
- NCT03710343 — Metformin for Motor and Cognitive Improvement in Children With Cerebral Palsy: A Feasibility Study · Phase 2 · completed
- NCT06129058 — Home-based Transcranial Direct Current Stimulation (tDCS) to Promote Social Communication and Behaviour in Children With · Phase 2 · recruiting
- NCT07312695 — Holly™ Community Trial · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04041713 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Holland Bloorview Kids Rehabilitation Hospital
- Last refreshed: 16 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04041713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing